Changeflow GovPing Healthcare & Life Sciences USPTO Patent Grant US12583892B2: Conus Peptides...
Routine Notice Added Final

USPTO Patent Grant US12583892B2: Conus Peptides for Neurodegenerative Conditions

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO has granted patent US12583892B2 to Technion Research and Development Foundation Limited for modified Conantokin peptides and their use in treating neurodegenerative conditions. The patent covers specific peptide forms, nucleic acids encoding them, and compositions for modulating NMDA receptors.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO patent grant US12583892B2 has been issued to Technion Research and Development Foundation Limited. The patent covers modified Conantokin peptides, nucleic acids encoding these peptides, and their application in treating neurodegenerative conditions by modulating NMDA receptors. The abstract details the invention, including chimeric polypeptides and their expression on target cell membranes.

This patent grant is a notification of intellectual property protection for a specific invention. It does not impose new regulatory obligations on regulated entities. Companies involved in pharmaceutical research and development, particularly in the areas of neurodegenerative diseases and peptide therapeutics, may find this patent relevant for competitive intelligence and freedom-to-operate analysis.

Archived snapshot

Mar 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Conus-based toxin peptides, nucleic acids encoding same and uses thereof in modulating NMDA receptors

Grant US12583892B2 Kind: B2 Mar 24, 2026

Assignee

TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LIMITED

Inventors

Shai Berlin, Ido Carmi, Shaden Zoabi

Abstract

Provided herein are modified forms of Conantokin peptides, including, modified Con-P peptides, nucleic acids encoding the same and compositions thereof. Further provided are nucleic acid molecules encoding for chimeric modified conantokin polypeptides to be expressed in or on a membrane of a target cells, compositions comprising the same and uses thereof for treating various neurodegenerative conditions.

CPC Classifications

C07K 14/435 C07K 14/43504 C07K 2319/03

Filing Date

2022-06-28

Application No.

17851430

Claims

16

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 24th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US12583892B2

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Therapeutic Research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Research & Development
Topics
Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!